These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 4743559)

  • 1. Effect of intraperitoneal pristane on established immunity to the adj-PC-5 plasmacytoma.
    Potter M; Walters JL
    J Natl Cancer Inst; 1973 Sep; 51(3):875-81. PubMed ID: 4743559
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination chemotherapy of advanced murine myeloma and subsequent resistance to tumor cell challenge.
    Teller MN; Bowie M; Mountain IM; Stock CC
    J Natl Cancer Inst; 1974 Mar; 52(3):667-71. PubMed ID: 4857022
    [No Abstract]   [Full Text] [Related]  

  • 3. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.
    Hengst JC; Mokyr MB; Dray S
    Cancer Res; 1980 Jul; 40(7):2135-41. PubMed ID: 6446379
    [No Abstract]   [Full Text] [Related]  

  • 4. Transplantable mouse plasma cell tumors in experimental chemotherapy.
    Teller MN; Abraham D; Bowie M; Carbone PP
    J Natl Cancer Inst; 1969 Jul; 43(1):123-31. PubMed ID: 5816022
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemotherapy and rate of kill of tumor cells in a mouse plasmacytoma.
    Hiramoto RN; Ghanta VK
    Cancer Res; 1974 Jul; 34(7):1738-42. PubMed ID: 4833918
    [No Abstract]   [Full Text] [Related]  

  • 6. Regulation of immune responses aginst the syngeneic ADJ-PC-5 plasmacytoma in BALB-c mice. III. Induction of specific T suppressor cells to the BALB/c plasmacytoma ADJ-PC-5 during early stages of tumorigenesis.
    Haubeck HD; Kölsch E
    Immunology; 1982 Nov; 47(3):503-10. PubMed ID: 6215340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of subcutaneously administered 2,6,10,14-tetramethylpentadecane on plasmacytoma growth.
    Platica M; Bojko C; Steiner G; Hollander VP
    Cancer Res; 1980 Jul; 40(7):2229-33. PubMed ID: 6248200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The allogeneic effect on tumor growth. II. Suppression of both ascitic and solid MOPC 315 plasmacytoma by the graft-vs-host reaction, with pathologic correlation.
    Osborne DP; Katz DH
    J Immunol; 1977 Apr; 118(4):1449-55. PubMed ID: 15035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The requirement of an adherent cell substratum for the growth of developing plasmacytoma cells in vivo.
    Cancro M; Potter M
    J Exp Med; 1976 Dec; 144(6):1554-67. PubMed ID: 1003103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity, antigenicity and mechanisms of tumor rejection of mineral-oil-induced plasmacytomas in syngeneic BALB/c mice.
    McCoy JL; Dean JH; Law LW; Williams J; McCoy NT; Holiman BJ
    Int J Cancer; 1974 Aug; 14(2):264-76. PubMed ID: 4142466
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effects of neonatal thymectomy on the immune reactions in BALB-c mice].
    Fantini F; Cattaneo R; Mignone V
    Folia Allergol (Roma); 1967; 14(5):320-8. PubMed ID: 5608827
    [No Abstract]   [Full Text] [Related]  

  • 12. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. I. Analysis of immune parameters involved.
    Cihak J; Ziegler HW; Kölsch E
    Immunology; 1981 May; 43(1):133-43. PubMed ID: 6265346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. II. Suppression of T-cell cytotoxicity by pretreatment of mice with subimmunogenic doses of tumour cells.
    Cihak J; Ziegler HW; Kölsch E
    Immunology; 1981 May; 43(1):145-52. PubMed ID: 6972902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunity against MOPC 104E plasmacytoma: effects of tumor size and time post therapy on in vivo tumor immunity.
    Lubet RA; Carlson DE
    J Natl Cancer Inst; 1978 May; 60(5):1107-11. PubMed ID: 642029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of monodansylcadaverine for effects on tumor growth.
    Yancey ST; Laki K
    J Natl Cancer Inst; 1974 Mar; 52(3):733-5. PubMed ID: 4826562
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumor immunity to murine plasma cell tumors. I. Tumor-associated transplantation antigens of NZB and BALB-c plasma cell tumors.
    Röllinghoff M; Rouse BT; Warner NL
    J Natl Cancer Inst; 1973 Jan; 50(1):159-72. PubMed ID: 4571237
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restorative effects of levamisole on cell-mediated immune responses following chemotherapy with aniline mustard in mice bearing ADJ-PC5 plasmacytoma.
    Padarathsingh ML; Dean JH; McCoy JL; Lewis DD; Northing JW
    Cancer Treat Rep; 1978 Nov; 62(11):1627-35. PubMed ID: 310338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary observations on immunity in BALB-c mice to myeloma tumor of BALB-c origin.
    Shearer WT; Graff RJ; Eisen HN
    Transplantation; 1972 Mar; 13(3):345-7. PubMed ID: 5021442
    [No Abstract]   [Full Text] [Related]  

  • 20. Quantitation of total-body tumor cells (MOPC 104E). I. Subcutaneous tumor model.
    Ghanta VK; Hiramoto RN
    J Natl Cancer Inst; 1974 Apr; 52(4):1199-202. PubMed ID: 4826588
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.